Clinical Trials Logo

Advanced Pancreatic Cancer clinical trials

View clinical trials related to Advanced Pancreatic Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06241352 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Statin Addition to Chemotherapy for Advanced Pancreatic Cancer

Start date: January 20, 2024
Phase: Phase 2
Study type: Interventional

The results of previous studies conducted by our team have revealed that the use of statins can more effectively hinder the growth of drug-resistant pancreatic cancer cells. The primary objective of this study was to investigate the role of statins in treating pancreatic cancer by assessing the safety and therapeutic impact of combining chemotherapy with statins in patients with advanced pancreatic cancer.

NCT ID: NCT06111274 Recruiting - Clinical trials for Advanced Pancreatic Cancer

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Start date: October 17, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: - Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. - Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: - Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B. - Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. - Complete the study procedures specified in the protocol, which is guided by researchers.

NCT ID: NCT06078787 Recruiting - Clinical trials for Metastatic Pancreatic Cancer

Olaparib in PALB2 Advanced Pancreatic Cancer

PALBOLA
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II, non-randomized, multicenter, unblinded open-label study of Olaparib in monotherapy in participants with advanced (locally advanced/metastatic) PALB2-related pancreatic cancer that have progressed after at least one treatment for advanced disease.

NCT ID: NCT05916261 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer

Start date: April 26, 2023
Phase: Early Phase 1
Study type: Interventional

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of Advanced Pancreatic Cancer. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

NCT ID: NCT05580445 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Start date: August 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, tolerability, pharmacokinetics and antineoplastic activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer

NCT ID: NCT05438797 Recruiting - Clinical trials for Advanced Pancreatic Cancer

The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Start date: April 2, 2021
Phase: Early Phase 1
Study type: Interventional

Clinical Study on the Safety and Efficacy of specific TIL-TCM cells for advanced relapse-refractory or metastatic pancreatic cancer.

NCT ID: NCT05380414 Recruiting - Clinical trials for Metastatic Pancreatic Cancer

Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The proposal is to implement a molecular screening program for advanced/metastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patients for rationale personalized medicine with targeted agents and/or combination involving a chemotherapy backbone.

NCT ID: NCT05162118 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

Start date: March 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161 combined with PD-1 inhibitor (Nivolumab Injection).

NCT ID: NCT05085548 Recruiting - Clinical trials for Advanced Pancreatic Cancer

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

Start date: October 29, 2021
Phase: Phase 1
Study type: Interventional

The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.

NCT ID: NCT05028933 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

IMC001 for Clinical Research on Advanced Digestive System Malignancies

Start date: September 30, 2021
Phase: Phase 1
Study type: Interventional

A Phase I Clinical Study of Autologous T cells modified with chimeric antigen receptor targeting EpCAM ( EPCAM CAR-T) in Patients with malignant tumors of the digestive system (including advanced gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) .